Clinical Trial Update: A Randomised, Single Centre, Double-blind, Two-period, Cross-over Trial in Healthy Subjects Investigating the Bioequivalence Between Subcutaneous Injections of Semaglutide Produced by Two Manufacturing Processes [Phase 1]

View source ↗

Summary

Phase 1 cross-over study in healthy subjects compared bioequivalence of subcutaneous semaglutide produced by two manufacturing processes; the study is completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• OZEMPIC (semaglutide)
• semaglutide (semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Healthy | Phase 1 | Status: COMPLETED